Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

Rouits E, Boisdron-Celle M, Dumont A, et al.: Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients. Clin Cancer Res, 2004. 10(15): 5151-5159. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + 1 G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics, 2002. 12(7): p. 555-8. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol, 1994: 12; 2640-2647. Longley D, Harkin D, Johnston P: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003, 3: 330 - 338. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics, 2000, 10(3): 217-223. Ridge SA, Sludden J, Brown O, et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol, 1998. 46(2): p. 151-6. Raida M, Schwabe W, Hausler P, et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res, 2001, 7(9): 2832-2839. Schwab M, Zanger UM, Marx C, et al.: Role of genetic and nongenetic factors for fluorouracil-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol, 2008, 26(13): 2131-38. Braun MS, Richman SD, Quirke P, et al.: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol, 2008. 26(16): p. 2690-8. McLeod HL, Sargent DJ, Marsh S, et al.: Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol, 2010. 28(20): p. 3227-33. Pare L, Paez D, Salazar J, et al.: Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br J Clin Pharmacol, 2010. 70(2): p. 268-72. Mattison LK, Fourie J, Hirao Y, et al.: The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13 C]dihydrouracil. Clin Cancer Res, 2006. 12(2): 549-555. Richman S, Braun MS, Adlard JW, et al.: Prognostic value of thymidylate synthase (TS) expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients. J Clin Oncol, 2006, Vol 24 (18 S): Abstract 10011. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J, 2001, 1(1): 65-70. Lecomte T, Ferraz JM, Zinzindohoue F, et al.: Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy. Clin Cancer Res, 2004, 10(17): 5880-5888. Braun MS, Richman SD, Thompson L, et al.: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol, 2009, 27(33): 5519-5528. **Large randomized assessment of molecular predictors of chemotherapy toxicity which did not confirm the promise of a number of putative predictors of outcome such as UGT1A1*28. Boige V, Mendibourne J, Pignon JP, et al.: Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol, 2010. 28(15): p. 2556-64. Sohn KJ, Croxford R, Yates Z, et al.: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst, 2004. 96(2): p. 134-44. Cohen V, Panet-Raymond V, Sabbaghian N, et al.: Methylenetetrahydrofolate Reductase Polymorphism in Advanced Colorectal Cancer: A Novel Genomic Predictor of Clinical Response to Fluoropyrimidine-based Chemotherapy. Clin Cancer Res, 2003. 9(5): p. 1611-1615. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, et al.: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol, 2010. 69(1): p. 58-66. Sharma R, Hoskins JM, Rivory LP, et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res, 2008. 14(3): p. 817-25. Ando Y, Ueoka H, Sugiyama T, et al.: Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit, 2002. 24(1): 111-116. Rahman A: Considerations for Integration of CDRH and CDER Regulations - A Case Study: Irinotecan and UGT1A1. March 2006. http://www.fda.gov/Cder/Offices/OODP/presentation/rahman.pdf Roth AD, Yan P, Dietrich D, et al.: Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 -SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II- III colon cancer (COC) patients. J Clin Oncol, 2008, 26(15 S): Abstract 4036. McLeod HL, Parodi L, Sargent DJ, et al.: UGT1A1*28 toxicity and outcome in advanced colorectal cancer: Results from the trial N9741. J Clin Oncol, 2006, 24(18 S): Abstract 3520. McLeod HL, Sargent DJ, Marsh S, et al.: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer: Results from an intergroup trial. J Clin Oncol, 2003, 22:253, Abstract 1013. Hoskins JM, Goldberg RM, Qu P, et al.: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst, 2007. 99(17): p. 1290-5. Roth AD, Yan P, Dietrich D, et al.: Does UGT1A1*28 homozygosity predict for severe toxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer. J Clin Oncol, 2008, 26(15 S): Abstract 277. Roth AD, Yan P, Dietrich D, et al.: Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 -SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II- III colon cancer (COC) patients. in Proc. ASCO. 2008. Cecchin E, Innocenti F, D’Andrea M, et al.: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin and Irinotecan. J Clin Oncol, 2009, 27(15): 2457-2465. Toffoli G, Cecchin E, Gasparini G, et al.: Genotype driven phase 1 study of Irinotecan administered in combination with Fluorouracil/Leucovorin in patients with metastatic colorectal cancer. J Clin Oncol, 2010, 28(5); 866-871. Mathijssen, RHJ, Marsh, S, Karlsson, MO, et al.: Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics. Clin Cancer Res, 2003, 9(9): 3246-3253. • Van der Bol JM, Mathijssen RHJ, Creemers GJM, et al.: A CYP3A4 phenotype-based dosing algorithm for individualized treatment of Irinotecan. Clin Cancer Res, 2010, 16(2): 736-742. This article demonstrates the potential of using midazolam metabolism and clearance to guide the dosing of irinotecan. Innocenti, F, Kroetz, DL, Schuetz, E, et al.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol, 2009, 27(16): 2604-2614. Chester JD, Joel SP, Cheeseman, SL, et al.: Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer. J Clin Oncol, 2003, 21(6): 1125-1132. Samimi G, Roohangiz S, Kuniyuki K, et al.: Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells. Clin Cancer Res, 2004. 10(14): p. 4661-4669. Lecomte T, Landi B, Beaune P, et al.: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res, 2006. 12(10): p. 3050-6. Ruzzo A, Graziano F, Loupakis F, et al.: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol, 2007. 25(10): p. 1247-54.1.